BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11906779)

  • 1. DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children.
    Santos JI; Martin A; De Leon T; Rivera L; Gaitán ME; Del Rio C; Oselka G; Cervantes Y; Rubio P; Clemens SA; de Mendonça JS
    Vaccine; 2002 Mar; 20(13-14):1887-93. PubMed ID: 11906779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America.
    Tregnaghi M; López P; Rocha C; Rivera L; David MP; Rüttimann R; Schuerman L
    Rev Panam Salud Publica; 2006 Mar; 19(3):179-88. PubMed ID: 16640847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.
    Faingezicht I; Avila-Aguerro ML; Cervantes Y; Fourneau M; Clemens SA
    Rev Panam Salud Publica; 2002 Oct; 12(4):247-57. PubMed ID: 12431356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S; Reyes M; Bermal N; Chandrasekaran V; Han HH; Bock HL; Lefevre I
    Hum Vaccin; 2008; 4(1):60-6. PubMed ID: 18376148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
    Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L
    Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months.
    Riedemann S; Reinhardt G; Jara J; Rios R; Wenzel MS; Willems P; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):215-22. PubMed ID: 12718838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity.
    Nolan T; Hogg G; Darcy MA; Skeljo M; Carlin J; Boslego J
    Vaccine; 2001 Feb; 19(15-16):2127-37. PubMed ID: 11228385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants.
    Kanra G; Kara A; Demiralp O; Contorni M; Hilbert AK; Spyr C; Viviani S
    Hum Vaccin; 2006; 2(4):155-60. PubMed ID: 17012890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
    Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P
    Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants.
    Bavdekar SB; Maiya PP; Subba Rao SD; Datta SK; Bock HL
    Indian Pediatr; 2007 Jul; 44(7):505-10. PubMed ID: 17684303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines.
    Prymula R; Plisek S
    Expert Opin Biol Ther; 2008 Apr; 8(4):503-13. PubMed ID: 18352853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age.
    Gabutti G; Zepp F; Schuerman L; Dentico P; Bamfi F; Soncini R; Habermehl P; Knuf M; Crovari P;
    Scand J Infect Dis; 2004; 36(8):585-92. PubMed ID: 15370670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial.
    Espinoza F; Tregnaghi M; Gentile A; Abarca K; Casellas J; Collard A; Lefevre I; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():297. PubMed ID: 20950456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.